AVM Biotechnology Employee Directory
Biotechnology ResearchWashington, United States11-50 Employees
AVM Biotechnology is a Seattle-based biotechnology research company focused on developing AVM0703, a proprietary formulation of dexamethasone designed for supra-pharmacologic dosing to mobilize the body's immune system. The program is described as triggering the production of endogenous gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T cells, with potential applications in cancer, autoimmune diseases, and infectious diseases, while emphasizing safety and reduced treatment-related suffering. Operating in the clinical-stage biotech space, AVM targets cancer, autoimmune disorders, and infectious diseases through immunomodulatory approaches. It was founded by Dr. Theresa Deisher and supports its research with a Scientific Advisory Board comprising leaders in cancer and immunology. In early 2024, AVM Biotechnology announced a collaboration with Xtacy Therapeutics, indicating active external partnerships alongside its development efforts.